Literature DB >> 30635632

Genetic and transcriptional landscape of plasma cells in POEMS syndrome.

Yuhei Nagao1,2, Naoya Mimura3,4, June Takeda5, Kenichi Yoshida5, Yusuke Shiozawa6, Motohiko Oshima7, Kazumasa Aoyama7, Atsunori Saraya7, Shuhei Koide7, Ola Rizq7, Yoshinori Hasegawa8, Yuichi Shiraishi9, Kenichi Chiba9, Hiroko Tanaka9, Dai Nishijima9, Yusuke Isshiki1,7, Kensuke Kayamori1,7, Chika Kawajiri-Manako1, Nagisa Oshima-Hasegawa1, Shokichi Tsukamoto1, Shio Mitsukawa1,10, Yusuke Takeda1, Chikako Ohwada1, Masahiro Takeuchi1, Tohru Iseki1,10, Sonoko Misawa11, Satoru Miyano9, Osamu Ohara12, Koutaro Yokote2, Emiko Sakaida1, Satoshi Kuwabara11, Masashi Sanada13, Atsushi Iwama7, Seishi Ogawa14, Chiaki Nakaseko15,16.   

Abstract

POEMS syndrome is a rare paraneoplastic disease associated with monoclonal plasma cells; however, the pathogenic importance of plasma cells remains unclear. We performed comprehensive genetic analyses of plasma cells in 20 patients with POEMS syndrome. Whole exome sequencing was performed in 11 cases and found a total of 308 somatic mutations in 285 genes. Targeted sequencing was performed in all 20 cases and identified 20 mutations in 7 recurrently mutated genes, namely KLHL6, LTB, EHD1, EML4, HEPHL1, HIPK1, and PCDH10. None of the driver gene mutations frequently found in multiple myeloma (MM) such as NRAS, KRAS, BRAF, and TP53 was detected. Copy number analysis showed chromosomal abnormalities shared with monoclonal gammopathy of undetermined significance (MGUS), suggesting a partial overlap in the early development of MGUS and POEMS syndrome. RNA sequencing revealed a transcription profile specific to POEMS syndrome when compared with normal plasma cells, MGUS and MM. Unexpectedly, disease-specific VEGFA expression was not increased in POEMS syndrome. Our study illustrates that the genetic and transcriptional profiles of plasma cells in POEMS syndrome are distinct from MM and MGUS, indicating unique function of clonal plasma cells in its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30635632     DOI: 10.1038/s41375-018-0348-x

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome.

Authors:  Sébastien Bender; Vincent Javaugue; Alexis Saintamand; Maria Victoria Ayala; Mehdi Alizadeh; Matthieu Filloux; Virginie Pascal; Nathalie Gachard; David Lavergne; Fabienne Auroy; Michel Cogné; Frank Bridoux; Christophe Sirac; Arnaud Jaccard
Journal:  Blood       Date:  2020-05-14       Impact factor: 22.113

2.  Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome.

Authors:  Taxiarchis V Kourelis; Dragan Jevremovic; Erik Jessen; Surendra Dasari; Jose C Villasboas; Angela Dispenzieri; Shaji Kumar
Journal:  Br J Haematol       Date:  2020-02-20       Impact factor: 6.998

3.  Missed diagnosis of POEMS syndrome with onset of progressive fatigue and numbness: a case report.

Authors:  Huan Shi; Xiaohong Jiang; Long Wang; Jiayan Zhou
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

4.  Identification of key genes in cutaneous squamous cell carcinoma: a transcriptome sequencing and bioinformatics profiling study.

Authors:  Dan-Dan Zou; Dan Xu; Yuan-Yuan Deng; Wen-Juan Wu; Juan Zhang; Ling Huang; Li He
Journal:  Ann Transl Med       Date:  2021-10

Review 5.  Update on the POEMS syndrome.

Authors:  Yu Ri Kim
Journal:  Blood Res       Date:  2022-04-30

Review 6.  From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.

Authors:  Andrea Visentin; Stefano Pravato; Francesca Castellani; Marta Campagnolo; Francesco Angotzi; Chiara Adele Cavarretta; Alessandro Cellini; Valeria Ruocco; Alessandro Salvalaggio; Alessandra Tedeschi; Livio Trentin; Chiara Briani
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.